Status:

NOT_YET_RECRUITING

CAffeine Use in Prolonged Oxygen Use in meConium aspIration Syndrome in Neonatal Outcomes (CAPUCINO)

Lead Sponsor:

University of Alberta

Conditions:

Meconium Aspiration Syndrome

Eligibility:

All Genders

10-14 years

Phase:

PHASE2

Brief Summary

When babies are stressed in the womb, they sometimes pass meconium in the amniotic fluid. When this happens, they may swallow the meconium-stained fluid into their lungs which may cause them to have p...

Eligibility Criteria

Inclusion

  • Infants born through meconium-stained amniotic fluid, and
  • Gestational age at or greater than 35+0 weeks at birth, and
  • Postnatal age of 10 to 14 days-old, and
  • Full enteral feeds either at semi-demand with a mix of gavage or oral feeds or at full-demand feeds by oral method, and
  • Stable respiratory condition for 24-48 hours prior to enrolment, and require respiratory support defined as: receiving non-invasive respiratory support including one of the following
  • High flow nasal cannula of less than or equal to 2L/min/Kg and FiO2 \<0.25, or
  • Low flow nasal cannula at \<100 ml/min

Exclusion

  • Preterm infants of less than 35+0 weeks gestation, or
  • Postnatal age younger than 9 day-old or older than 15 day-old, or
  • Parenteral nutrition supplementation or full enteral feeds by gavage, or
  • Received caffeine within 5 days prior to enrolment, or
  • Currently, receiving invasive respiratory support or continuous positive airway pressure (CPAP), or
  • During the study period with the administration of study medication, the infant cannot receive steroids including dexamethasone, hydrocortisone and budesonide by intravenous, enteral or inhalational route, or
  • Medical diseases including infections, electrolytes or acid-base imbalances, significant anemia, systematic and metabolic disorders that contribute to respiratory insufficiency other than meconium aspiration syndrome, or
  • Congenital anomalies including but not limited to respiratory tract malformations, congenital heart diseases, and syndromal abnormalities.

Key Trial Info

Start Date :

December 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2027

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT06972108

Start Date

December 1 2025

End Date

December 31 2027

Last Update

November 18 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.